Loading
A phase 1/2 trial of MT-4561 in head and neck squamous cell carcinoma, non-small-cell lung cancer, oesophageal cancer, gastric & gastro-oesophageal junction cancer, biliary tract cancer and pancreatic ductal adenocarcinoma, run by Tanabe Pharma America, Inc., now recruiting.
A Study of MT-4561 in Patients With Various Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06943521 by Tanabe Pharma America, Inc., with 27 participants planned, started 2025-04-18 and due to reach its primary completion in 2028-08. Interventions recorded: MT-4561.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.